The global market for Monoclonal Antibody for Gastric Cancer was valued at US$ 1261 million in the year 2023 and is projected to reach a revised size of US$ 2787 million by 2030, growing at a CAGR of 12.0% during the forecast period.

Monoclonal Antibody for Gastric Cancer Market

Monoclonal Antibodies for Gastric Cancer are a class of lab-made proteins targeting specific antigens on the surface of gastric cancer cells. They can recognize and bind these antigens with high specificity, so as to activate the immune system to attack gastric cancer cells or directly inhibit the growth and spread of cancer cells. They are an important part of targeted therapies for the treatment of gastric cancer.

North American market for Monoclonal Antibody for Gastric Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Monoclonal Antibody for Gastric Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Monoclonal Antibody for Gastric Cancer include Genentech, Eli Lilly & Co, Bristol Myers Squibb Co, Merck & Co., Inc, BeiGene Ltd, Astellas Pharma, Inc., Innovent Biologics, Inc, CStone Pharmaceuticals, Henlius, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody for Gastric Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody for Gastric Cancer.

The Monoclonal Antibody for Gastric Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Monoclonal Antibody for Gastric Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Monoclonal Antibody for Gastric Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Monoclonal Antibody for Gastric Cancer Market Report

Report Metric	Details
Report Name	Monoclonal Antibody for Gastric Cancer Market
Accounted market size in year	US$ 1261 million
Forecasted market size in 2030	US$ 2787 million
CAGR	12.0%
Base Year	year
Forecasted years	2025 - 2030
by Type	4 mg/mL 5 mg/mL 10 mg/mL
by Application	Hospital Clinic Others
Production by Region	North America Europe China
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Genentech, Eli Lilly & Co, Bristol Myers Squibb Co, Merck & Co., Inc, BeiGene Ltd, Astellas Pharma, Inc., Innovent Biologics, Inc, CStone Pharmaceuticals, Henlius
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Monoclonal Antibody for Gastric Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Monoclonal Antibody for Gastric Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Monoclonal Antibody for Gastric Cancer Market growing?

Ans: The Monoclonal Antibody for Gastric Cancer Market witnessing a CAGR of 12.0% during the forecast period 2025-2030.

What is the Monoclonal Antibody for Gastric Cancer Market size in 2030?

Ans: The Monoclonal Antibody for Gastric Cancer Market size in 2030 will be US$ 2787 million.

Who are the main players in the Monoclonal Antibody for Gastric Cancer Market report?

Ans: The main players in the Monoclonal Antibody for Gastric Cancer Market are Genentech, Eli Lilly & Co, Bristol Myers Squibb Co, Merck & Co., Inc, BeiGene Ltd, Astellas Pharma, Inc., Innovent Biologics, Inc, CStone Pharmaceuticals, Henlius

What are the Application segmentation covered in the Monoclonal Antibody for Gastric Cancer Market report?

Ans: The Applications covered in the Monoclonal Antibody for Gastric Cancer Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Monoclonal Antibody for Gastric Cancer Market report?

Ans: The Types covered in the Monoclonal Antibody for Gastric Cancer Market report are 4 mg/mL, 5 mg/mL, 10 mg/mL

1 Monoclonal Antibody for Gastric Cancer Market Overview

1.1 Product Definition

1.2 Monoclonal Antibody for Gastric Cancer by Type

1.2.1 Global Monoclonal Antibody for Gastric Cancer Market Value Comparison by Type (2024-2030)

1.2.2 4 mg/mL

1.2.3 5 mg/mL

1.2.4 10 mg/mL

1.3 Monoclonal Antibody for Gastric Cancer by Application

1.3.1 Global Monoclonal Antibody for Gastric Cancer Market Value by Application (2024-2030)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Monoclonal Antibody for Gastric Cancer Market Size Estimates and Forecasts

1.4.1 Global Monoclonal Antibody for Gastric Cancer Revenue 2019-2030

1.4.2 Global Monoclonal Antibody for Gastric Cancer Sales 2019-2030

1.4.3 Global Monoclonal Antibody for Gastric Cancer Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Monoclonal Antibody for Gastric Cancer Market Competition by Manufacturers

2.1 Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Manufacturers (2019-2024)

2.2 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Monoclonal Antibody for Gastric Cancer Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Monoclonal Antibody for Gastric Cancer, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Product Type & Application

2.7 Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Date of Enter into This Industry

2.8 Global Monoclonal Antibody for Gastric Cancer Market Competitive Situation and Trends

2.8.1 Global Monoclonal Antibody for Gastric Cancer Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Monoclonal Antibody for Gastric Cancer Players Market Share by Revenue

2.8.3 Global Monoclonal Antibody for Gastric Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Monoclonal Antibody for Gastric Cancer Market Scenario by Region

3.1 Global Monoclonal Antibody for Gastric Cancer Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2019-2030

3.2.1 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2019-2024

3.2.2 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2025-2030

3.3 Global Monoclonal Antibody for Gastric Cancer Revenue by Region: 2019-2030

3.3.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Region: 2019-2024

3.3.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Region: 2025-2030

3.4 North America Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Country

3.4.1 North America Monoclonal Antibody for Gastric Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Monoclonal Antibody for Gastric Cancer Sales by Country (2019-2030)

3.4.3 North America Monoclonal Antibody for Gastric Cancer Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Country

3.5.1 Europe Monoclonal Antibody for Gastric Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Monoclonal Antibody for Gastric Cancer Sales by Country (2019-2030)

3.5.3 Europe Monoclonal Antibody for Gastric Cancer Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Region

3.6.1 Asia Pacific Monoclonal Antibody for Gastric Cancer Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Region (2019-2030)

3.6.3 Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Country

3.7.1 Latin America Monoclonal Antibody for Gastric Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Monoclonal Antibody for Gastric Cancer Sales by Country (2019-2030)

3.7.3 Latin America Monoclonal Antibody for Gastric Cancer Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Country

3.8.1 Middle East and Africa Monoclonal Antibody for Gastric Cancer Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (2019-2030)

3.8.3 Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Monoclonal Antibody for Gastric Cancer Sales by Type (2019-2030)

4.1.1 Global Monoclonal Antibody for Gastric Cancer Sales by Type (2019-2024)

4.1.2 Global Monoclonal Antibody for Gastric Cancer Sales by Type (2025-2030)

4.1.3 Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2019-2030)

4.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2019-2030)

4.2.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2019-2024)

4.2.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2025-2030)

4.2.3 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2019-2030)

4.3 Global Monoclonal Antibody for Gastric Cancer Price by Type (2019-2030)

5 Segment by Application

5.1 Global Monoclonal Antibody for Gastric Cancer Sales by Application (2019-2030)

5.1.1 Global Monoclonal Antibody for Gastric Cancer Sales by Application (2019-2024)

5.1.2 Global Monoclonal Antibody for Gastric Cancer Sales by Application (2025-2030)

5.1.3 Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2019-2030)

5.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2019-2030)

5.2.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2019-2024)

5.2.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2025-2030)

5.2.3 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2019-2030)

5.3 Global Monoclonal Antibody for Gastric Cancer Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Genentech

6.1.1 Genentech Company Information

6.1.2 Genentech Description and Business Overview

6.1.3 Genentech Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Genentech Monoclonal Antibody for Gastric Cancer Product Portfolio

6.1.5 Genentech Recent Developments/Updates

6.2 Eli Lilly & Co

6.2.1 Eli Lilly & Co Company Information

6.2.2 Eli Lilly & Co Description and Business Overview

6.2.3 Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Product Portfolio

6.2.5 Eli Lilly & Co Recent Developments/Updates

6.3 Bristol Myers Squibb Co

6.3.1 Bristol Myers Squibb Co Company Information

6.3.2 Bristol Myers Squibb Co Description and Business Overview

6.3.3 Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Product Portfolio

6.3.5 Bristol Myers Squibb Co Recent Developments/Updates

6.4 Merck & Co., Inc

6.4.1 Merck & Co., Inc Company Information

6.4.2 Merck & Co., Inc Description and Business Overview

6.4.3 Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Product Portfolio

6.4.5 Merck & Co., Inc Recent Developments/Updates

6.5 BeiGene Ltd

6.5.1 BeiGene Ltd Company Information

6.5.2 BeiGene Ltd Description and Business Overview

6.5.3 BeiGene Ltd Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.5.4 BeiGene Ltd Monoclonal Antibody for Gastric Cancer Product Portfolio

6.5.5 BeiGene Ltd Recent Developments/Updates

6.6 Astellas Pharma, Inc.

6.6.1 Astellas Pharma, Inc. Company Information

6.6.2 Astellas Pharma, Inc. Description and Business Overview

6.6.3 Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Product Portfolio

6.6.5 Astellas Pharma, Inc. Recent Developments/Updates

6.7 Innovent Biologics, Inc

6.7.1 Innovent Biologics, Inc Company Information

6.7.2 Innovent Biologics, Inc Description and Business Overview

6.7.3 Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Product Portfolio

6.7.5 Innovent Biologics, Inc Recent Developments/Updates

6.8 CStone Pharmaceuticals

6.8.1 CStone Pharmaceuticals Company Information

6.8.2 CStone Pharmaceuticals Description and Business Overview

6.8.3 CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.8.4 CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Product Portfolio

6.8.5 CStone Pharmaceuticals Recent Developments/Updates

6.9 Henlius

6.9.1 Henlius Company Information

6.9.2 Henlius Description and Business Overview

6.9.3 Henlius Monoclonal Antibody for Gastric Cancer Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Henlius Monoclonal Antibody for Gastric Cancer Product Portfolio

6.9.5 Henlius Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Monoclonal Antibody for Gastric Cancer Industry Chain Analysis

7.2 Monoclonal Antibody for Gastric Cancer Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Monoclonal Antibody for Gastric Cancer Production Mode & Process

7.4 Monoclonal Antibody for Gastric Cancer Sales and Marketing

7.4.1 Monoclonal Antibody for Gastric Cancer Sales Channels

7.4.2 Monoclonal Antibody for Gastric Cancer Distributors

7.5 Monoclonal Antibody for Gastric Cancer Customers

8 Monoclonal Antibody for Gastric Cancer Market Dynamics

8.1 Monoclonal Antibody for Gastric Cancer Industry Trends

8.2 Monoclonal Antibody for Gastric Cancer Market Drivers

8.3 Monoclonal Antibody for Gastric Cancer Market Challenges

8.4 Monoclonal Antibody for Gastric Cancer Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Genentech Inc

Eli Lilly & Co

Bristol-Myers Squibb Co

Merck& Co. Inc

BeiGene Ltd

Astellas Pharma Inc

Innovent Biologics, Inc.

CStone Pharmaceuticals

Henlius

List of Tables

Table 1. Global Monoclonal Antibody for Gastric Cancer Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Monoclonal Antibody for Gastric Cancer Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Monoclonal Antibody for Gastric Cancer Market Competitive Situation by Manufacturers in 2023

Table 4. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Monoclonal Antibody for Gastric Cancer Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Monoclonal Antibody for Gastric Cancer Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Monoclonal Antibody for Gastric Cancer, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Product Type & Application

Table 12. Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Monoclonal Antibody for Gastric Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody for Gastric Cancer as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Monoclonal Antibody for Gastric Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Monoclonal Antibody for Gastric Cancer Sales by Region (2019-2024) & (K Units)

Table 18. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2019-2024)

Table 19. Global Monoclonal Antibody for Gastric Cancer Sales by Region (2025-2030) & (K Units)

Table 20. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2025-2030)

Table 21. Global Monoclonal Antibody for Gastric Cancer Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2019-2024)

Table 23. Global Monoclonal Antibody for Gastric Cancer Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2025-2030)

Table 25. North America Monoclonal Antibody for Gastric Cancer Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Monoclonal Antibody for Gastric Cancer Sales by Country (2019-2024) & (K Units)

Table 27. North America Monoclonal Antibody for Gastric Cancer Sales by Country (2025-2030) & (K Units)

Table 28. North America Monoclonal Antibody for Gastric Cancer Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Monoclonal Antibody for Gastric Cancer Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Monoclonal Antibody for Gastric Cancer Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Monoclonal Antibody for Gastric Cancer Sales by Country (2019-2024) & (K Units)

Table 32. Europe Monoclonal Antibody for Gastric Cancer Sales by Country (2025-2030) & (K Units)

Table 33. Europe Monoclonal Antibody for Gastric Cancer Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Monoclonal Antibody for Gastric Cancer Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Monoclonal Antibody for Gastric Cancer Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Monoclonal Antibody for Gastric Cancer Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Monoclonal Antibody for Gastric Cancer Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Monoclonal Antibody for Gastric Cancer Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Monoclonal Antibody for Gastric Cancer Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) by Type (2019-2024)

Table 51. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) by Type (2025-2030)

Table 52. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2019-2024)

Table 53. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2025-2030)

Table 54. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2019-2024)

Table 57. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2025-2030)

Table 58. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Type (2019-2024)

Table 59. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Type (2025-2030)

Table 60. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) by Application (2019-2024)

Table 61. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) by Application (2025-2030)

Table 62. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2019-2024)

Table 63. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2025-2030)

Table 64. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2019-2024)

Table 67. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2025-2030)

Table 68. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Application (2019-2024)

Table 69. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Application (2025-2030)

Table 70. Genentech Company Information

Table 71. Genentech Description and Business Overview

Table 72. Genentech Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Genentech Monoclonal Antibody for Gastric Cancer Product

Table 74. Genentech Recent Developments/Updates

Table 75. Eli Lilly & Co Company Information

Table 76. Eli Lilly & Co Description and Business Overview

Table 77. Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Product

Table 79. Eli Lilly & Co Recent Developments/Updates

Table 80. Bristol Myers Squibb Co Company Information

Table 81. Bristol Myers Squibb Co Description and Business Overview

Table 82. Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Product

Table 84. Bristol Myers Squibb Co Recent Developments/Updates

Table 85. Merck & Co., Inc Company Information

Table 86. Merck & Co., Inc Description and Business Overview

Table 87. Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Product

Table 89. Merck & Co., Inc Recent Developments/Updates

Table 90. BeiGene Ltd Company Information

Table 91. BeiGene Ltd Description and Business Overview

Table 92. BeiGene Ltd Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. BeiGene Ltd Monoclonal Antibody for Gastric Cancer Product

Table 94. BeiGene Ltd Recent Developments/Updates

Table 95. Astellas Pharma, Inc. Company Information

Table 96. Astellas Pharma, Inc. Description and Business Overview

Table 97. Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Product

Table 99. Astellas Pharma, Inc. Recent Developments/Updates

Table 100. Innovent Biologics, Inc Company Information

Table 101. Innovent Biologics, Inc Description and Business Overview

Table 102. Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Product

Table 104. Innovent Biologics, Inc Recent Developments/Updates

Table 105. CStone Pharmaceuticals Company Information

Table 106. CStone Pharmaceuticals Description and Business Overview

Table 107. CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Product

Table 109. CStone Pharmaceuticals Recent Developments/Updates

Table 110. Henlius Company Information

Table 111. Henlius Description and Business Overview

Table 112. Henlius Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Henlius Monoclonal Antibody for Gastric Cancer Product

Table 114. Henlius Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Monoclonal Antibody for Gastric Cancer Distributors List

Table 118. Monoclonal Antibody for Gastric Cancer Customers List

Table 119. Monoclonal Antibody for Gastric Cancer Market Trends

Table 120. Monoclonal Antibody for Gastric Cancer Market Drivers

Table 121. Monoclonal Antibody for Gastric Cancer Market Challenges

Table 122. Monoclonal Antibody for Gastric Cancer Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of Monoclonal Antibody for Gastric Cancer

Figure 2. Global Monoclonal Antibody for Gastric Cancer Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Monoclonal Antibody for Gastric Cancer Market Share by Type: 2023 & 2030

Figure 4. 4 mg/mL Product Picture

Figure 5. 5 mg/mL Product Picture

Figure 6. 10 mg/mL Product Picture

Figure 7. Global Monoclonal Antibody for Gastric Cancer Market Value by Application (2024-2030) & (US$ Million)

Figure 8. Global Monoclonal Antibody for Gastric Cancer Market Share by Application: 2023 & 2030

Figure 9. Hospital

Figure 10. Clinic

Figure 11. Others

Figure 12. Global Monoclonal Antibody for Gastric Cancer Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Monoclonal Antibody for Gastric Cancer Market Size (2019-2030) & (US$ Million)

Figure 14. Global Monoclonal Antibody for Gastric Cancer Sales (2019-2030) & (K Units)

Figure 15. Global Monoclonal Antibody for Gastric Cancer Average Price (US$/Unit) & (2019-2030)

Figure 16. Monoclonal Antibody for Gastric Cancer Report Years Considered

Figure 17. Monoclonal Antibody for Gastric Cancer Sales Share by Manufacturers in 2023

Figure 18. Global Monoclonal Antibody for Gastric Cancer Revenue Share by Manufacturers in 2023

Figure 19. Global 5 and 10 Largest Monoclonal Antibody for Gastric Cancer Players: Market Share by Revenue in Monoclonal Antibody for Gastric Cancer in 2023

Figure 20. Monoclonal Antibody for Gastric Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 21. Global Monoclonal Antibody for Gastric Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2019-2030)

Figure 23. North America Monoclonal Antibody for Gastric Cancer Revenue Market Share by Country (2019-2030)

Figure 24. United States Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2019-2030)

Figure 27. Europe Monoclonal Antibody for Gastric Cancer Revenue Market Share by Country (2019-2030)

Figure 28. Germany Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2019-2030)

Figure 35. China Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Southeast Asia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2019-2030)

Figure 43. Mexico Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Colombia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2019-2030)

Figure 48. Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue Market Share by Country (2019-2030)

Figure 49. Turkey Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. UAE Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Global Sales Market Share of Monoclonal Antibody for Gastric Cancer by Type (2019-2030)

Figure 53. Global Revenue Market Share of Monoclonal Antibody for Gastric Cancer by Type (2019-2030)

Figure 54. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Type (2019-2030)

Figure 55. Global Sales Market Share of Monoclonal Antibody for Gastric Cancer by Application (2019-2030)

Figure 56. Global Revenue Market Share of Monoclonal Antibody for Gastric Cancer by Application (2019-2030)

Figure 57. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Application (2019-2030)

Figure 58. Monoclonal Antibody for Gastric Cancer Value Chain

Figure 59. Monoclonal Antibody for Gastric Cancer Production Process

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions